Mural Oncology (MURA) Competitors $3.18 +0.04 (+1.27%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MURA vs. LXEO, FATE, DMAC, ZNTL, TNYA, ATAI, ACRV, ACRS, MOLN, and SOPHShould you be buying Mural Oncology stock or one of its competitors? The main competitors of Mural Oncology include Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), DiaMedica Therapeutics (DMAC), Zentalis Pharmaceuticals (ZNTL), Tenaya Therapeutics (TNYA), Atai Life Sciences (ATAI), Acrivon Therapeutics (ACRV), Aclaris Therapeutics (ACRS), Molecular Partners (MOLN), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. Mural Oncology vs. Lexeo Therapeutics Fate Therapeutics DiaMedica Therapeutics Zentalis Pharmaceuticals Tenaya Therapeutics Atai Life Sciences Acrivon Therapeutics Aclaris Therapeutics Molecular Partners SOPHiA GENETICS Lexeo Therapeutics (NASDAQ:LXEO) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment. Does the media refer more to LXEO or MURA? In the previous week, Lexeo Therapeutics had 5 more articles in the media than Mural Oncology. MarketBeat recorded 5 mentions for Lexeo Therapeutics and 0 mentions for Mural Oncology. Lexeo Therapeutics' average media sentiment score of 0.00 equaled Mural Oncology'saverage media sentiment score. Company Overall Sentiment Lexeo Therapeutics Neutral Mural Oncology Neutral Which has higher valuation and earnings, LXEO or MURA? Lexeo Therapeutics has higher revenue and earnings than Mural Oncology. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K319.47-$66.39M-$3.16-1.99Mural OncologyN/AN/A-$207.45M-$9.14-0.35 Do institutionals and insiders hold more shares of LXEO or MURA? 60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 80.2% of Mural Oncology shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Mural Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in LXEO or MURA? Lexeo Therapeutics received 14 more outperform votes than Mural Oncology when rated by MarketBeat users. CompanyUnderperformOutperformLexeo TherapeuticsOutperform Votes19100.00% Underperform VotesNo VotesMural OncologyOutperform Votes5100.00% Underperform VotesNo Votes Is LXEO or MURA more profitable? Lexeo Therapeutics' return on equity of -57.66% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -57.66% -48.18% Mural Oncology N/A -70.10%-61.30% Do analysts prefer LXEO or MURA? Lexeo Therapeutics currently has a consensus price target of $23.80, indicating a potential upside of 278.98%. Mural Oncology has a consensus price target of $16.00, indicating a potential upside of 403.14%. Given Mural Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Mural Oncology is more favorable than Lexeo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Mural Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 SummaryLexeo Therapeutics beats Mural Oncology on 9 of the 13 factors compared between the two stocks. Ad ProsperityPubIf you see ONE chart today… make it this one$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.And expects this underappreciated niche to continue rallying well into 2026. Get Mural Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for MURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MURA vs. The Competition Export to ExcelMetricMural OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.12M$6.59B$5.15B$9.08BDividend YieldN/A3.00%5.12%4.26%P/E Ratio-0.3510.5987.1517.20Price / SalesN/A196.061,140.21117.12Price / CashN/A57.1643.2337.85Price / Book0.205.094.794.78Net Income-$207.45M$151.83M$120.55M$225.60M7 Day Performance-7.56%-1.08%-1.46%-1.36%1 Month Performance-5.07%-4.57%13.77%0.20%1 Year Performance-28.22%8.80%28.68%15.29% Mural Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MURAMural Oncology2.9673 of 5 stars$3.18+1.3%$16.00+403.1%-28.2%$54.12MN/A-0.35119LXEOLexeo Therapeutics2.2178 of 5 stars$7.01+1.9%$23.80+239.5%-59.6%$231.79M$650,000.00-2.1858Gap DownFATEFate Therapeutics3.5618 of 5 stars$2.02+10.1%$6.75+235.0%-50.9%$229.50M$13.45M-1.22550DMACDiaMedica Therapeutics0.5071 of 5 stars$5.33-0.9%$7.00+31.3%+124.9%$227.91MN/A-9.6120Gap DownZNTLZentalis Pharmaceuticals2.0095 of 5 stars$3.17+2.6%$10.00+215.5%-79.2%$225.89MN/A-1.24160TNYATenaya Therapeutics3.9078 of 5 stars$2.83+2.9%$17.33+512.5%-44.7%$224.19MN/A-1.91110ATAIAtai Life Sciences1.8899 of 5 stars$1.33-2.2%$9.00+576.7%-15.0%$223.18M$331,000.00-1.6883ACRVAcrivon Therapeutics0.955 of 5 stars$7.01-0.7%$23.67+237.6%+34.5%$218.26MN/A-2.6158ACRSAclaris Therapeutics3.7058 of 5 stars$3.05-5.3%$8.80+188.5%+154.2%$217.87M$27.08M-5.8386MOLNMolecular Partners0.3457 of 5 stars$5.35-1.5%N/A+11.2%$215.80M$6.00M-2.53180Positive NewsSOPHSOPHiA GENETICS2.4536 of 5 stars$3.28flat$6.50+98.2%-28.4%$214.45M$62.37M-3.01520Positive News Related Companies and Tools Related Companies Lexeo Therapeutics Competitors Fate Therapeutics Competitors DiaMedica Therapeutics Competitors Zentalis Pharmaceuticals Competitors Tenaya Therapeutics Competitors Atai Life Sciences Competitors Acrivon Therapeutics Competitors Aclaris Therapeutics Competitors Molecular Partners Competitors SOPHiA GENETICS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MURA) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MURA Stock Alerts